Company Filing History:
Years Active: 2013-2014
Title: Innovations of Agnes Nowakowski
Introduction
Agnes Nowakowski is a prominent inventor based in Austin, Texas. She has made significant contributions to the field of cancer research through her innovative work on antibody compositions. With a total of two patents to her name, her inventions focus on targeted therapies for various types of cancer.
Latest Patents
Agnes Nowakowski's latest patents include compositions and methods related to the Ovr110 antibody. These isolated antibodies and antigen-binding fragments are directed against Ovr110, which is expressed in several cancers, including head and neck, ovarian, endometrial, kidney, pancreatic, lung, and breast cancer. The patents provide methods for producing these antibodies and their use in killing Ovr110-expressing cancer cells. Additionally, they describe how the anti-Ovr110 antibodies can modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells, both in vitro and in vivo. The patents also include compositions comprising an anti-Ovr110 antibody and a carrier, as well as articles of manufacture or kits. Furthermore, isolated nucleic acids encoding the anti-Ovr110 antibody, expression vectors containing these nucleic acids, and host cells containing the vectors are also provided.
Career Highlights
Agnes Nowakowski is currently associated with Diadexus, Inc., where she continues her research and development in the field of cancer therapeutics. Her work has been instrumental in advancing the understanding of targeted cancer treatments.
Collaborations
Some of her notable coworkers include Jackie Papkoff and Gundo Diedrich, who have collaborated with her on various projects related to cancer research.
Conclusion
Agnes Nowakowski's innovative contributions to cancer research through her patented antibody compositions highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in targeted cancer therapies.